International Stem Cell (ISCO) Operating Expenses (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Operating Expenses of $2.5 million for Q4 2025, up 3.05% year-over-year from $2.4 million in Q4 2024, and up 8.48% quarter-over-quarter from $2.3 million in Q3 2025.
International Stem Cell (ISCO) Operating Expenses (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Operating Expenses for 16 consecutive years, with $2.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses rose 3.05% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $9.4 million (up 2.34% YoY), while the FY2025 annual figure was $9.4 million, up 2.34% from the prior year.
- Operating Expenses improved to $2.5 million in Q4 2025 per ISCO's latest filing, from $2.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $2.5 million in Q4 2025 and bottomed at $2.0 million in Q2 2023.
- Historically, Operating Expenses has averaged $2.2 million across 5 years, with a median of $2.3 million in 2021.
- Annual changes were most pronounced in 2021 — Operating Expenses decreased 20.96% — and 2024, when it rose 10.7%.
- International Stem Cell's Operating Expenses stood at $2.2 million in 2021, then climbed by 9.37% to $2.4 million in 2022, then declined by 2.36% to $2.3 million in 2023, then increased by 3.55% to $2.4 million in 2024, then increased by 3.05% to $2.5 million in 2025.
- Business Quant data shows ISCO's Operating Expenses at $2.5 million in Q4 2025, $2.3 million in Q3 2025, and $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.71 Mn |
| Dec 31, 2025 | 2.47 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.28 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Dec 31, 2023 | 2.31 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 1.99 Mn |
| Mar 31, 2023 | 2.08 Mn |
| Dec 31, 2022 | 2.37 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 2.00 Mn |
| Dec 31, 2021 | 2.17 Mn |
| Sep 30, 2021 | 2.47 Mn |
| Jun 30, 2021 | 2.24 Mn |